The specific B-cell depleting anti-CD20 monoclonal antibody rituximab (RTX) is effective in terms of the treatment of various immune-mediated glomerulopathies. The administration of RTX has been shown to be reliable and highly effective particularly in patients with ANCA-associated vasculitis, which is manifested predominantly with non-nephrotic proteinuria. Stable long-term B-cell depletion is usually readily attained in such patients using standard dosing regimens. However, in patients with nephrotic syndrome and non-selective proteinuria, the RTX pharmacokinetics is altered profoundly and RTX does not maintain high enough levels for a sufficiently long period, which may render RTX treatment ineffective. Since complement-derived cytotoxicity is one of the important modes of action of RTX, hypocomplementemia, frequently associated with systemic lupus erythematodes, may act to hamper the efficacy of RTX in the treatment of patients with lupus nephritis. This review provides a description of RTX pharmacokinetics and pharmacodynamics in several selected glomerulopathies, as well as the impact of proteinuria, anti-drug antibodies and other clinical variables on the clearance and volume of distribution of RTX. The impact of plasmapheresis and peritoneal dialysis on the clearance of RTX is also discussed in the paper. A review is provided of the potential association between pharmacokinetic and pharmacodynamic alterations in various kidney-affecting glomerular diseases, the sustainability of B-cell depletion and the clinical efficacy of RTX, with proposals for potential dosing implications. The role of therapeutic drug monitoring in treatment tailoring is also discussed, and various previously tested RTX dosing schedules are compared in terms of their clinical and laboratory treatment responses. Since alternative anti-CD20 molecules may prove effective in RTX unresponsive patients, their pharmacokinetics, pharmacodynamics and current role in the treatment of glomerulopathies are also mentioned.

Department of Nephrology 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czechia

Department of Pharmacology 1st Faculty of Medicine Charles University and General University Hospital Prague Prague Czechia

See more in PubMed

Wise LM, Stohl W. Belimumab and rituximab in systemic lupus erythematosus: A tale of two b cell-targeting agents. Front Med (2020) 7(303). doi: 10.3389/fmed.2020.00303 PubMed DOI PMC

Fervenza FC, Appel GB, Barbour SJ, Rovin BH, Lafayette RA, Aslam N, et al. . Rituximab or cyclosporine in the treatment of membranous nephropathy. New Engl J Med (2019) 381(1):36–46. doi: 10.1056/NEJMoa1814427 PubMed DOI

Elisa L, Francesco Z, James B. Rituximab in the treatment of immune thrombocytopenia: what is the role of this agent in 2019? Haematologica (2019) 104(6):1124–35. doi: 10.3324/haematol.2019.218883 PubMed DOI PMC

Leandro MJ. B-cell subpopulations in humans and their differential susceptibility to depletion with anti-CD20 monoclonal antibodies. Arthritis Res Ther (2013) 15 Suppl 1(Suppl 1):S3–S. doi: 10.1186/ar3908 PubMed DOI PMC

Cragg MS, Walshe CA, Ivanov AO, Glennie MJ. The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun (2005) 8:140–74. doi: 10.1159/000082102 PubMed DOI

Casan JML, Wong J, Northcott MJ, Opat S. Anti-CD20 monoclonal antibodies: reviewing a revolution. Hum Vaccin Immunother (2018) 14(12):2820–41. doi: 10.1080/21645515.2018.1508624 PubMed DOI PMC

DiLillo DJ, Hamaguchi Y, Ueda Y, Yang K, Uchida J, Haas KM, et al. . Maintenance of long-lived plasma cells and serological memory despite mature and memory b cell depletion during CD20 immunotherapy in mice. J Immunol (2008) 180(1):361–71. doi: 10.4049/jimmunol.180.1.361 PubMed DOI

Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S, et al. . Rituximab-associated hypogammaglobulinemia: incidence, predictors and outcomes in patients with multi-system autoimmune disease. J Autoimmun (2015) 57:60–5. doi: 10.1016/j.jaut.2014.11.009 PubMed DOI

Sinha R, Agrawal N, Xue Y, Chanchlani R, Pradhan S, Raina R, et al. . Use of rituximab in paediatric nephrology. Arch Dis Child. (2021) 106(11):1058–65. doi: 10.1136/archdischild-2020-321211 PubMed DOI PMC

Wang X, Du W, Zhang X, Li P. The influence of different disease states on rituximab pharmacokinetics. Curr Drug Metab (2020) 21(12):938–46. doi: 10.2174/1389200221666200719004035 PubMed DOI

Fogueri U, Cheungapasitporn W, Bourne D, Fervenza FC, Joy MS. Rituximab exhibits altered pharmacokinetics in patients with membranous nephropathy. Ann pharmacother (2019) 53(4):357–63. doi: 10.1177/1060028018803587 PubMed DOI PMC

Boyer-Suavet S, Andreani M, Lateb M, Savenkoff B, Brglez V, Benzaken S, et al. . Neutralizing anti-rituximab antibodies and relapse in membranous nephropathy treated with rituximab. Front Immunol (2020) 10(3069). doi: 10.3389/fimmu.2019.03069 PubMed DOI PMC

Du FH, Mills EA, Mao-Draayer Y. Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment. Auto Immun Highlights (2017) 8(1):12. doi: 10.1007/s13317-017-0100-y PubMed DOI PMC

Robak T, Robak E. New anti-CD20 monoclonal antibodies for the treatment of b-cell lymphoid malignancies. BioDrugs. (2011) 25(1):13–25. doi: 10.2165/11539590-000000000-00000 PubMed DOI

Anolik JH, Campbell D, Felgar RE, Young F, Sanz I, Rosenblatt J, et al. . The relationship of FcgammaRIIIa genotype to degree of b cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheumatol (2003) 48(2):455–9. doi: 10.1002/art.10764 PubMed DOI

Mysler EF, Spindler AJ, Guzman R, Bijl M, Jayne D, Furie RA, et al. . Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: Results from a randomized, double-blind, phase III study. Arthritis Rheum (2013) 65(9):2368–79. doi: 10.1002/art.38037 PubMed DOI

Sorensen PS, Blinkenberg M. The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects. Ther Adv Neurol Disord (2016) 9(1):44–52. doi: 10.1177/1756285615601933 PubMed DOI PMC

Klein C, Lammens A, Schäfer W, Georges G, Schwaiger M, Mössner E, et al. . Epitope interactions of monoclonal antibodies targeting CD20 and their relationship to functional properties. mAbs. (2013) 5(1):22–33. doi: 10.4161/mabs.22771 PubMed DOI PMC

Teeling JL, Mackus WJ, Wiegman LJ, van den Brakel JH, Beers SA, French RR, et al. . The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20. J Immunol (2006) 177(1):362–71. doi: 10.4049/jimmunol.177.1.362 PubMed DOI

Hagenbeek A, Gadeberg O, Johnson P, Pedersen LM, Walewski J, Hellmann A, et al. . First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial. Blood. (2008) 111(12):5486–95. doi: 10.1182/blood-2007-10-117671 PubMed DOI

Teeling JL, French RR, Cragg MS, van den Brakel J, Pluyter M, Huang H, et al. . Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas. Blood. (2004) 104(6):1793–800. doi: 10.1182/blood-2004-01-0039 PubMed DOI

Beers SA, Chan CHT, James S, French RR, Attfield KE, Brennan CM, et al. . Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in b-cell depletion regardless of complement activation. Blood. (2008) 112(10):4170–7. doi: 10.1182/blood-2008-04-149161 PubMed DOI PMC

Luo C, Wu G, Huang X, Ma Y, Zhang Y, Song Q, et al. . Efficacy and safety of new anti-CD20 monoclonal antibodies versus rituximab for induction therapy of CD20+ b-cell non-Hodgkin lymphomas: a systematic review and meta-analysis. Sci Rep (2021) 11(1):3255. doi: 10.1038/s41598-021-82841-w PubMed DOI PMC

Brad R, Sharon A, Jonathan B, Frank B, Burdge KA, Daniel C, et al. . KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int (2021) 100(4s):S1–s276. doi: 10.1016/j.kint.2021.05.021 PubMed DOI

Gauckler P, Shin JI, Alberici F, Audard V, Bruchfeld A, Busch M, et al. . Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - what is known and what is still unknown? Autoimmun Rev (2020) 19(11):102671. doi: 10.1016/j.autrev.2020.102671 PubMed DOI

Stolyar L, Lahita RG, Panush RS. Rituximab use as induction therapy for lupus nephritis: a systematic review. Lupus. (2020) 29(8):892–912. doi: 10.1177/0961203320928412 PubMed DOI

Smith RM, Jones RB, Specks U, Bond S, Nodale M, Aljayyousi R, et al. . Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis. Ann Rheum Diseases (2020) 79(9):1243. doi: 10.1136/annrheumdis-2019-216863 PubMed DOI PMC

Stone JH, Merkel PA, Spiera R, Seo P, Langford CA, Hoffman GS, et al. . Rituximab versus cyclophosphamide for ANCA-associated vasculitis. N Engl J Med (2010) 363(3):221–32. doi: 10.1056/NEJMoa0909905 PubMed DOI PMC

Jones RB, Furuta S, Cohen Tervaert JW, Hauser T, Luqmani R, Morgan MD, et al. . Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis: 2-year results of a randomised trial. Ann Rheum Diseases (2015) 74(6):1178. doi: 10.1136/annrheumdis-2014-206404 PubMed DOI

van Daalen EE, Rizzo R, Kronbichler A, Wolterbeek R, Bruijn JA, Jayne DR, et al. . Effect of rituximab on malignancy risk in patients with ANCA-associated vasculitis. Ann Rheum Dis (2017) 76(6):1064–9. doi: 10.1136/annrheumdis-2016-209925 PubMed DOI

Guillevin L, Pagnoux C, Karras A, Khouatra C, Aumaître O, Cohen P, et al. . Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis. N Engl J Med (2014) 371(19):1771–80. doi: 10.1056/NEJMoa1404231 PubMed DOI

Lu W, Gong S, Li J, Luo H, Wang Y. Efficacy and safety of rituximab in the treatment of membranous nephropathy: A systematic review and meta-analysis. Med (Baltimore) (2020) 99(16):e19804. doi: 10.1097/MD.0000000000019804 PubMed DOI PMC

Gauckler P, Shin JI, Alberici F, Audard V, Bruchfeld A, Busch M, et al. . Rituximab in membranous nephropathy. Kidney Int Rep (2021) 6(4):881–93. doi: 10.1016/j.ekir.2020.12.035 PubMed DOI PMC

Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, et al. . Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet (9950) 2014:1273–81:384. doi: 10.1016/S0140-6736(14)60541-9 PubMed DOI

Kronbichler A, Kerschbaum J, Fernandez-Fresnedo G, Hoxha E, Kurschat CE, Busch M, et al. . Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review. Am J Nephrol (2014) 39(4):322–30. doi: 10.1159/000360908 PubMed DOI

Guitard J, Hebral AL, Fakhouri F, Joly D, Daugas E, Rivalan J, et al. . Rituximab for minimal-change nephrotic syndrome in adulthood: predictive factors for response, long-term outcomes and tolerance. Nephrol Dial Transpl (2014) 29(11):2084–91. doi: 10.1093/ndt/gfu209 PubMed DOI

Shalhoub R. Pathogenesis of lipoid nephrosis: A disorder of T-cell function. Lancet (1974) 304(7880):556–60. doi: 10.1016/S0140-6736(74)91880-7 PubMed DOI

Colucci M, Oniszczuk J, Vivarelli M, Audard V. B-cell dysregulation in idiopathic nephrotic syndrome: What we know and what we need to discover. Front Immunol (2022) 13. doi: 10.3389/fimmu.2022.823204 PubMed DOI PMC

Colucci M, Carsetti R, Cascioli S, Casiraghi F, Perna A, Ravà L, et al. . B cell reconstitution after rituximab treatment in idiopathic nephrotic syndrome. J Am Soc Nephrol (2016) 27(6):1811–22. doi: 10.1681/ASN.2015050523 PubMed DOI PMC

Bhatia D, Sinha A, Hari P, Sopory S, Saini S, Puraswani M, et al. . Rituximab modulates T- and b-lymphocyte subsets and urinary CD80 excretion in patients with steroid-dependent nephrotic syndrome. Pediatr Res (2018) 84(4):520–6. doi: 10.1038/s41390-018-0088-7 PubMed DOI

Fribourg M, Cioni M, Ghiggeri G, Cantarelli C, Leventhal JS, Budge K, et al. . CyTOF-enabled analysis identifies class-switched b cells as the main lymphocyte subset associated with disease relapse in children with idiopathic nephrotic syndrome. Front Immunol (2021) 12. doi: 10.3389/fimmu.2021.726428 PubMed DOI PMC

Boumediene A, Vachin P, Sendeyo K, Oniszczuk J, Zhang SY, Henique C, et al. . NEPHRUTIX: A randomized, double-blind, placebo vs rituximab-controlled trial assessing T-cell subset changes in minimal change nephrotic syndrome. J Autoimmun (2018) 88:91–102. doi: 10.1016/j.jaut.2017.10.006 PubMed DOI

Ravani P, Colucci M, Bruschi M, Vivarelli M, Cioni M, DiDonato A, et al. . Human or chimeric monoclonal anti-CD20 antibodies for children with nephrotic syndrome: A superiority randomized trial. J Am Soc Nephrol (2021) 32(10):2652–63. doi: 10.1681/ASN.2021040561 PubMed DOI PMC

Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, et al. . Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheumatol (2012) 64(4):1215–26. doi: 10.1002/art.34359 PubMed DOI

Li K, Yu Y, Gao Y, Zhao F, Liang Z, Gao J. Comparative effectiveness of rituximab and common induction therapies for lupus nephritis: A systematic review and network meta-analysis. Front Immunol (2022) 13. doi: 10.3389/fimmu.2022.859380 PubMed DOI PMC

Gomez Mendez LM, Cascino MD, Garg J, Katsumoto TR, Brakeman P, Dall’Era M, et al. . Peripheral blood b cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol (2018) 13(10):1502. doi: 10.2215/CJN.01070118 PubMed DOI PMC

Sfikakis PP, Boletis JN, Lionaki S, Vigklis V, Fragiadaki KG, Iniotaki A, et al. . Remission of proliferative lupus nephritis following b cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheumatol (2005) 52(2):501–13. doi: 10.1002/art.20858 PubMed DOI

Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, et al. . A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction. J Am Soc Nephrol (2017) 28(4):1306. doi: 10.1681/ASN.2016060640 PubMed DOI PMC

Paul F, Cartron G. Infusion-related reactions to rituximab: frequency, mechanisms and predictors. Expert Rev Clin Immunol (2019) 15(4):383–9. doi: 10.1080/1744666X.2019.1562905 PubMed DOI

Tavakolpour S, Alesaeidi S, Darvishi M, GhasemiAdl M, Darabi-Monadi S, Akhlaghdoust M, et al. . A comprehensive review of rituximab therapy in rheumatoid arthritis patients. Clin Rheumatol (2019) 38(11):2977–94. doi: 10.1007/s10067-019-04699-8 PubMed DOI

Kaegi C, Wuest B, Schreiner J, Steiner UC, Vultaggio A, Matucci A, et al. . Systematic review of safety and efficacy of rituximab in treating immune-mediated disorders. Front Immunol (2019) 10:1990–. doi: 10.3389/fimmu.2019.01990 PubMed DOI PMC

Jyssum I, Kared H, Tran TT, Tveter AT, Provan SA, Sexton J, et al. . Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study. Lancet Rheumatol (2022) 4(3):e177–e87. doi: 10.1016/S2665-9913(21)00394-5 PubMed DOI PMC

Tieu J, Smith RM, Gopaluni S, Kumararatne DS, McClure M, Manson A, et al. . Rituximab associated hypogammaglobulinemia in autoimmune disease. Front Immunol (2021) 12. doi: 10.3389/fimmu.2021.671503 PubMed DOI PMC

Zonozi R, Wallace ZS, Laliberte K, Huizenga NR, Rosenthal JM, Rhee EP, et al. . Incidence, clinical features, and outcomes of late-onset neutropenia from rituximab for autoimmune disease. Arthritis Rheumatol (2021) 73(2):347–54. doi: 10.1002/art.41501 PubMed DOI PMC

Arai Y, Yamashita K, Mizugishi K, Nishikori M, Hishizawa M, Kondo T, et al. . Risk factors for late-onset neutropenia after rituximab treatment of b-cell lymphoma. Hematology. (2015) 20(4):196–202. doi: 10.1179/1607845414Y.0000000188 PubMed DOI

Bennett CL, Focosi D, Socal MP, Bian JC, Nabhan C, Hrushesky WJ, et al. . Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the southern network on adverse reactions. Lancet Haematol (2021) 8(8):e593–604. doi: 10.1016/S2352-3026(21)00167-8 PubMed DOI

Bensalem A, Cartron G, Specks U, Mulleman D, Gyan E, Cornec D, et al. . The influence of underlying disease on rituximab pharmacokinetics may be explained by target-mediated drug disposition. Clin Pharmacokinet (2022) 61(3):423–37. doi: 10.1007/s40262-021-01081-3 PubMed DOI

Golay J, Semenzato G, Rambaldi A, Foà R, Gaidano G, Gamba E, et al. . Lessons for the clinic from rituximab pharmacokinetics and pharmacodynamics. MAbs. (2013) 5(6):826–37. doi: 10.4161/mabs.26008 PubMed DOI PMC

Puisset F, White-Koning M, Kamar N, Huart A, Haberer F, Blasco H, et al. . Population pharmacokinetics of rituximab with or without plasmapheresis in kidney patients with antibody-mediated disease. Br J Clin Pharmacol (2013) 76(5):734–40. doi: 10.1111/bcp.12098 PubMed DOI PMC

Salles G, Barrett M, Foà R, Maurer J, O’Brien S, Valente N, et al. . Rituximab in b-cell hematologic malignancies: A review of 20 years of clinical experience. Adv Ther (2017) 34(10):2232–73. doi: 10.1007/s12325-017-0612-x PubMed DOI PMC

Solal-Celigny P. Rituximab by subcutaneous route. Expert Rev Hematol (2015) 8(2):147–53. doi: 10.1586/17474086.2015.1024651 PubMed DOI

Breedveld F, Agarwal S, Yin M, Ren S, Li NF, Shaw TM, et al. . Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol (2007) 47(9):1119–28. doi: 10.1177/0091270007305297 PubMed DOI

Cornec D, Kabat BF, Mills JR, Cheu M, Hummel AM, Schroeder DR, et al. . Pharmacokinetics of rituximab and clinical outcomes in patients with anti-neutrophil cytoplasmic antibody associated vasculitis. Rheumatology (2018) 57(4):639–50. doi: 10.1093/rheumatology/kex484 PubMed DOI PMC

Müller C, Murawski N, Wiesen MH, Held G, Poeschel V, Zeynalova S, et al. . The role of sex and weight on rituximab clearance and serum elimination half-life in elderly patients with DLBCL. Blood. (2012) 119(14):3276–84. doi: 10.1182/blood-2011-09-380949 PubMed DOI

Chen Y, Shen Q, Dong M, Xiong Y, Xu H, Li Z. Population pharmacokinetics of rituximab in pediatric patients with frequent-relapsing or steroid-dependent nephrotic syndrome. Front Pharmacol (2021) 12:725665. doi: 10.3389/fphar.2021.725665 PubMed DOI PMC

Regazzi MB, Iacona I, Avanzini MA, Arcaini L, Merlini G, Perfetti V, et al. . Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings. Ther Drug Monit (2005) 27(6):785–92. doi: 10.1097/01.ftd.0000184162.60197.c1 PubMed DOI

Tout M, Casasnovas O, Meignan M, Lamy T, Morschhauser F, Salles G, et al. . Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a lymphoma study association report. Blood. (2017) 129(19):2616–23. doi: 10.1182/blood-2016-10-744292 PubMed DOI

Gibiansky E, Gibiansky L, Buchheit V, Frey N, Brewster M, Fingerle-Rowson G, et al. . Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study. Br J Clin Pharmacol (2019) 85(9):1935–45. doi: 10.1111/bcp.13974 PubMed DOI PMC

Hiroshima Y, Tajima K, Shiono Y, Suzuki I, Kouno K, Yamamoto M, et al. . Rituximab pharmacokinetics in ascites and serum in the treatment of follicular lymphoma with massive ascites. Ann Hematol (2012) 91(9):1499–500. doi: 10.1007/s00277-012-1410-9 PubMed DOI PMC

Counsilman CE, Jol-van der Zijde CM, Stevens J, Cransberg K, Bredius RGM, Sukhai RN. Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome. Pediatr Nephrol (2015) 30(8):1367–70. doi: 10.1007/s00467-015-3120-8 PubMed DOI PMC

Klink DT, van Elburg RM, Schreurs MWJ, van Well GTJ. Rituximab administration in third trimester of pregnancy suppresses neonatal b-cell development. Clin Dev Immunol (2008) 2008:271363. doi: 10.1155/2008/271363 PubMed DOI PMC

Beum PV, Peek EM, Lindorfer MA, Beurskens FJ, Engelberts PJ, Parren PWHI, et al. . Loss of CD20 and bound CD20 antibody from opsonized b cells occurs more rapidly because of trogocytosis mediated by fc receptor-expressing effector cells than direct internalization by the b cells. J Immunol (2011) 187(6):3438. doi: 10.4049/jimmunol.1101189 PubMed DOI

Assouline S, Buccheri V, Delmer A, Gaidano G, McIntyre C, Brewster M, et al. . Pharmacokinetics and safety of subcutaneous rituximab plus fludarabine and cyclophosphamide for patients with chronic lymphocytic leukaemia. Br J Clin Pharmacol (2015) 80(5):1001–9. doi: 10.1111/bcp.12662 PubMed DOI PMC

Bensalem A, Mulleman D, Paintaud G, Azzopardi N, Gouilleux-Gruart V, Cornec D, et al. . Non-linear rituximab pharmacokinetics and complex relationship between rituximab concentrations and anti-neutrophil cytoplasmic antibodies (ANCA) in ANCA-associated vasculitis: The RAVE trial revisited. Clin Pharmacokinet (2020) 59(4):519–30. doi: 10.1007/s40262-019-00826-5 PubMed DOI

Vaisman-Mentesh A, Gutierrez-Gonzalez M, DeKosky BJ, Wine Y. The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies. Front Immunol (2020) 11. doi: 10.3389/fimmu.2020.01951 PubMed DOI PMC

Looney RJ, Anolik JH, Campbell D, Felgar RE, Young F, Arend LJ, et al. . B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheumatol (2004) 50(8):2580–9. doi: 10.1002/art.20430 PubMed DOI

Jacobs R, Langer-Jacobus T, Duong M, Stahl K, Haller H, Schmidt RE, et al. . Detection and quantification of rituximab in the human urine. J Immunol Methods (2017) 451:118–21. doi: 10.1016/j.jim.2017.09.001 PubMed DOI

Stahl K, Duong M, Schwarz A, Wagner AD, Haller H, Schiffer M, et al. . Kinetics of rituximab excretion into urine and peritoneal fluid in two patients with nephrotic syndrome. Case Rep Nephrol (2017) 2017:1372859. doi: 10.1155/2017/1372859 PubMed DOI PMC

Jillella AP, Dainer PM, Kallab AM, Ustun C. Treatment of a patient with end-stage renal disease with rituximab: pharmacokinetic evaluation suggests rituximab is not eliminated by hemodialysis. Am J hematol (2002) 71(3):219–22. doi: 10.1002/ajh.10213 PubMed DOI

Azzopardi N, Francois M, Laurent E, Paintaud G, Birmele B. Influence of plasma exchange on rituximab pharmacokinetics. Br J Clin Pharmacol (2013) 76(3):486–8. doi: 10.1111/bcp.12167 PubMed DOI PMC

Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. CPT Pharmacometrics Syst Pharmacol (2017) 6(9):576–88. doi: 10.1002/psp4.12224 PubMed DOI PMC

Fervenza FC, Abraham RS, Erickson SB, Irazabal MV, Eirin A, Specks U, et al. . Rituximab therapy in idiopathic membranous nephropathy: A 2-year study. Clin J Am Soc Nephrol (2010) 5(12):2188. doi: 10.2215/CJN.05080610 PubMed DOI PMC

Fervenza FC, Cosio FG, Erickson SB, Specks U, Herzenberg AM, Dillon JJ, et al. . Rituximab treatment of idiopathic membranous nephropathy. Kidney Int (2008) 73(1):117–25. doi: 10.1038/sj.ki.5002628 PubMed DOI

Chen M, Liu J, Xiong Y, Xu G. Treatment of idiopathic membranous nephropathy for moderate or severe proteinuria: A systematic review and network meta-analysis. Int J Clin Pract (2022) 2022:4996239. doi: 10.1155/2022/4996239 PubMed DOI PMC

Boyer-Suavet S, Andreani M, Cremoni M, Brglez V, Benzaken S, Bernard G, et al. . Rituximab bioavailability in primary membranous nephropathy. Nephrol Dial Transpl (2019) 34(8):1423–5. doi: 10.1093/ndt/gfz041 PubMed DOI

Seitz-Polski B, Dahan K, Debiec H, Rousseau A, Andreani M, Zaghrini C, et al. . High-dose rituximab and early remission in PLA2R1-related membranous nephropathy. Clin J Am Soc Nephrol (2019) 14(8):1173. doi: 10.2215/CJN.11791018 PubMed DOI PMC

Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, et al. . Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol (2009) 24(7):1321–8. doi: 10.1007/s00467-009-1191-0 PubMed DOI

Woo KT, Wu A, Lau YK, Lee EJ, Edmondson RP, Pwee HS, et al. . Protein selectivity in IgA nephropathy. Nephron. (1986) 42(3):236–9. doi: 10.1159/000183673 PubMed DOI

Cravedi P, Ruggenenti P, Sghirlanzoni MC, Remuzzi G. Titrating rituximab to circulating b cells to optimize lymphocytolytic therapy in idiopathic membranous nephropathy. Clin J Am Soc Nephrol (2007) 2(5):932. doi: 10.2215/CJN.01180307 PubMed DOI

Moroni G, Depetri F, Del Vecchio L, Gallelli B, Raffiotta F, Giglio E, et al. . Low-dose rituximab is poorly effective in patients with primary membranous nephropathy. Nephrol Dial Transpl (2017) 32(10):1691–6. doi: 10.1093/ndt/gfw251 PubMed DOI

Dahan K, Johannet C, Esteve E, Plaisier E, Debiec H, Ronco P. Retreatment with rituximab for membranous nephropathy with persistently elevated titers of anti-phospholipase A2 receptor antibody. Kidney Int (2019) 95(1):233–4. doi: 10.1016/j.kint.2018.08.045 PubMed DOI

Cassia MA, Alberici F, Jones RB, Smith RM, Casazza G, Urban ML, et al. . Rituximab as maintenance treatment for systemic lupus erythematosus: A multicenter observational study of 147 patients. Arthritis Rheumatol (2019) 71(10):1670–80. doi: 10.1002/art.40932 PubMed DOI

Hartinger JM, Satrapová V, Hrušková Z, Tesař V. Tolerance and safety of rapid 2-hour infusion of rituximab in patients with kidney-affecting autoimmune diseases and glomerulonephritides: a single-centre experience. Eur J Hosp Pharm (2018) 26:210–3. doi: 10.1136/ejhpharm-2017-001454 PubMed DOI PMC

Raffray L, Guillevin L. Rituximab treatment of ANCA-associated vasculitis. Expert Opin Biol Ther (2020) 20(8):899–910. doi: 10.1080/14712598.2020.1748597 PubMed DOI

McAdoo SP, Bedi R, Tarzi R, Griffith M, Pusey CD, Cairns TD. Ofatumumab for b cell depletion therapy in ANCA-associated vasculitis: a single-centre case series. Rheumatology (2016) 55(8):1437–42. doi: 10.1093/rheumatology/kew199 PubMed DOI PMC

Urlaub D, Zhao S, Blank N, Bergner R, Claus M, Tretter T, et al. . Activation of natural killer cells by rituximab in granulomatosis with polyangiitis. Arthritis Res Ther (2019) 21(1):277–. doi: 10.1186/s13075-019-2054-0 PubMed DOI PMC

Klomjit N, Zand L. Rituximab is preferable to cyclophosphamide for treatment of membranous nephropathy: COMMENTARY. Kidney 360 (2021) 2(11):1702–5. doi: 10.34067/KID.0002492021 PubMed DOI PMC

Podestà MA, Ruggiero B, Remuzzi G, Ruggenenti P. Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness. BMJ Case Rep (2020) 13(1):e232896. doi: 10.1136/bcr-2019-232896 PubMed DOI PMC

Teisseyre M, Boyer-Suavet S, Crémoni M, Brglez V, Esnault V, Seitz-Polski B. Analysis and management of rituximab resistance in PLA2R1-associated membranous nephropathy. Kidney Int Rep (2021) 6(4):1183–8. doi: 10.1016/j.ekir.2021.01.022 PubMed DOI PMC

Klomjit N, Fervenza FC, Zand L. Successful treatment of patients with refractory PLA(2)R-associated membranous nephropathy with obinutuzumab: A report of 3 cases. Am J Kidney Dis (2020) 76(6):883–8. doi: 10.1053/j.ajkd.2020.02.444 PubMed DOI

Sethi S, Kumar S, Lim K, Jordan SC. Obinutuzumab is effective for the treatment of refractory membranous nephropathy. Kidney Int Rep (2020) 5(9):1515–8. doi: 10.1016/j.ekir.2020.06.030 PubMed DOI PMC

Schmidt T, Schulze M, Harendza S, Hoxha E. Successful treatment of PLA(2)R1-antibody positive membranous nephropathy with ocrelizumab. J Nephrol (2021) 34(2):603–6. doi: 10.1007/s40620-020-00874-2 PubMed DOI PMC

Ahn YH, Kang HG, Lee JM, Choi HJ, Ha I-S, Cheong HI. Development of antirituximab antibodies in children with nephrotic syndrome. Pediatr Nephrol (2014) 29(8):1461–4. doi: 10.1007/s00467-014-2794-7 PubMed DOI

Basu B. Ofatumumab for rituximab-resistant nephrotic syndrome. New Engl J Med (2014) 370(13):1268–70. doi: 10.1056/NEJMc1308488 PubMed DOI

Wang C-S, Liverman RS, Garro R, George RP, Glumova A, Karp A, et al. . Ofatumumab for the treatment of childhood nephrotic syndrome. Pediatr Nephrol (2017) 32(5):835–41. doi: 10.1007/s00467-017-3621-8 PubMed DOI PMC

Bonanni A, Rossi R, Murtas C, Ghiggeri GM. Low-dose ofatumumab for rituximab-resistant nephrotic syndrome. BMJ Case Rep (2015) 2015:bcr2015210208. doi: 10.1136/bcr-2015-210208 PubMed DOI PMC

Vivarelli M, Colucci M, Bonanni A, Verzani M, Serafinelli J, Emma F, et al. . Ofatumumab in two pediatric nephrotic syndrome patients allergic to rituximab. Pediatr Nephrol (2017) 32(1):181–4. doi: 10.1007/s00467-016-3498-y PubMed DOI

Fujinaga S, Sakuraya K. Single infusion of low-dose ofatumumab in a child with complicated nephrotic syndrome with anti-rituximab antibodies. Pediatr Nephrol (2018) 33(3):527–8. doi: 10.1007/s00467-017-3866-2 PubMed DOI

Ravani P, Pisani I, Bodria M, Caridi G, Degl’Innocenti ML, Ghiggeri GM. Low-dose ofatumumab for multidrug-resistant nephrotic syndrome in children: a randomized placebo-controlled trial. Pediatr Nephrol (2020) 35(6):997–1003. doi: 10.1007/s00467-020-04481-y PubMed DOI

Ravani P, Colucci M, Bruschi M, Vivarelli M, Cioni M, DiDonato A, et al. . Human or chimeric monoclonal anti-CD20 antibodies for children with nephrotic syndrome: A superiority randomized trial. J Am Soc Nephrol (2021) 32(10)2652–63. doi: 10.1681/ASN.2021040561 PubMed DOI PMC

Reynolds BC, Lamb A, Jones CA, Yadav P, Tyerman KS, Geddes CC. UK Experience of ofatumumab in recurrence of focal segmental glomerulosclerosis post-kidney transplant. Pediatr Nephrol (2021) 37(1):199–207. doi: 10.1007/s00467-021-05248-9 PubMed DOI PMC

Bernard J, Lalieve F, Sarlat J, Perrin J, Dehoux L, Boyer O, et al. . Ofatumumab treatment for nephrotic syndrome recurrence after pediatric renal transplantation. Pediatr Nephrol (2020) 35(8):1499–506. doi: 10.1007/s00467-020-04567-7 PubMed DOI

Solomon S, Zolotnitskaya A, Del Rio M. Ofatumumab in post-transplantation recurrence of focal segmental glomerulosclerosis in a child. Pediatr Transpl (2019) 23(4):e13413. doi: 10.1111/petr.13413 PubMed DOI

Colucci M, Labbadia R, Vivarelli M, Camassei FD, Emma F, Dello Strologo L. Ofatumumab rescue treatment in post-transplant recurrence of focal segmental glomerulosclerosis. Pediatr Nephrol (2020) 35(2):341–5. doi: 10.1007/s00467-019-04365-w PubMed DOI

Kienzl-Wagner K, Rosales A, Scheidl S, Giner T, Bösmüller C, Rudnicki M, et al. . Successful management of recurrent focal segmental glomerulosclerosis. Am J Transpl (2018) 18(11):2818–22. doi: 10.1111/ajt.14998 PubMed DOI PMC

Reddy V, Jayne D, Close D, Isenberg D. B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumaband implications for study design. Arthritis Res Ther (2013) 15(1):S2. doi: 10.1186/ar3910 PubMed DOI PMC

Merrill JT, Neuwelt CM, Wallace DJ, Shanahan JC, Latinis KM, Oates JC, et al. . Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheumatol (2010) 62(1):222–33. doi: 10.1002/art.27233 PubMed DOI PMC

Furie R, Aroca G, Alvarez A, Fragoso-Loyo H, Santillan EZ, Rovin B, et al. . Two-year results from a randomized, controlled study of obinutuzumab for proliferative lupus nephritis. Arthritis Rheum (2020) 72:1984–5. doi: 10.1002/art.41538 DOI

Haarhaus ML, Svenungsson E, Gunnarsson I. Ofatumumab treatment in lupus nephritis patients. Clin Kidney J (2016) 9(4):552–5. doi: 10.1093/ckj/sfw022 PubMed DOI PMC

Thornton CC, Ambrose N, Ioannou Y. Ofatumumab: a novel treatment for severe systemic lupus erythematosus. Rheumatology. (2015) 54(3):559–60. doi: 10.1093/rheumatology/keu475 PubMed DOI

Masoud S, McAdoo SP, Bedi R, Cairns TD, Lightstone L. Ofatumumab for b cell depletion in patients with systemic lupus erythematosus who are allergic to rituximab. Rheumatology (2018) 57(7):1156–61. doi: 10.1093/rheumatology/key042 PubMed DOI

Md Yusof MY, Shaw D, El-Sherbiny YM, Dunn E, Rawstron AC, Emery P, et al. . Predicting and managing primary and secondary non-response to rituximab using b-cell biomarkers in systemic lupus erythematosus. Ann rheum diseases (2017) 76(11):1829–36. doi: 10.1136/annrheumdis-2017-211191 PubMed DOI PMC

Hassan SU, Md Yusof MY, Emery P, Dass S, Vital EM. Biologic sequencing in systemic lupus erythematosus: After secondary non-response to rituximab, switching to humanised anti-CD20 agent is more effective than belimumab. Front Med (2020) 7:498–. doi: 10.3389/fmed.2020.00498 PubMed DOI PMC

Lundberg S, Westergren E, Smolander J, Bruchfeld A. B cell-depleting therapy with rituximab or ofatumumab in immunoglobulin a nephropathy or vasculitis with nephritis. Clin Kidney J (2017) 10(1):20–6. doi: 10.1093/ckj/sfw106 PubMed DOI PMC

Struemper H, Sale M, Patel BR, Østergaard M, Österborg A, Wierda WG, et al. . Population pharmacokinetics of ofatumumab in patients with chronic lymphocytic leukemia, follicular lymphoma, and rheumatoid arthritis. J Clin Pharmacol (2014) 54(7):818–27. doi: 10.1002/jcph.268 PubMed DOI

Coiffier B, Losic N, Rønn BB, Lepretre S, Pedersen LM, Gadeberg O, et al. . Pharmacokinetics and pharmacokinetic/pharmacodynamic associations of ofatumumab, a human monoclonal CD20 antibody, in patients with relapsed or refractory chronic lymphocytic leukaemia: a phase 1–2 study. Br J Haematol (2010) 150(1):58–71. doi: 10.1111/j.1365-2141.2010.08193.x PubMed DOI

Gibiansky E, Petry C, Mercier F, Günther A, Herman A, Kappos L, et al. . Ocrelizumab in relapsing and primary progressive multiple sclerosis: Pharmacokinetic and pharmacodynamic analyses of OPERA I, OPERA II and ORATORIO. Br J Clin Pharmacol (2021) 87(6):2511–20. doi: 10.1111/bcp.14658 PubMed DOI PMC

Morschhauser F, Leonard JP, Fayad L, Coiffier B, Petillon M-O, Coleman M, et al. . Humanized anti-CD20 antibody, veltuzumab, in Refractory/Recurrent non-hodgkin’s lymphoma: Phase I/II results. J Clin Oncol (2009) 27(20):3346–53. doi: 10.1200/JCO.2008.19.9117 PubMed DOI

Truedsson L, Bengtsson AA, Sturfelt G. Complement deficiencies and systemic lupus erythematosus. Autoimmunity. (2007) 40(8):560–6. doi: 10.1080/08916930701510673 PubMed DOI

Basu B, Angeletti A, Islam B, Ghiggeri GM. New and old anti-CD20 monoclonal antibodies for nephrotic syndrome. where we are? Front Immunol (2022) 13:805697. doi: 10.3389/fimmu.2022.805697 PubMed DOI PMC